Posted by Michael Wonder on 07 Feb 2017
Alexion 'extremely disappointed' with NICE ruling on costly Strensiq
7 February 2017 - Once again, the U.K.’s drug cost watchdogs are catching flak from the industry after issuing a restricted recommendation for Alexion’s pricey rare-disease med Strensiq.
In a final evaluation determination, the National Institute for Health and Care Excellence recommended the drug for treating patients with perinatal- and infantile-onset hypophosphatasia under certain conditions and with a confidential discount.
Citing a “very high” cost and “significant uncertainties” about Strensiq’s long-term benefits, however, the institute’s experts decided not to recommend the med in children with juvenile-onset disease. The med also failed to win a nod for adults with juvenile-onset disease.
